Dabur India faces USFDA Import Alert 66-40 in 2026

What happened and why it matters

Dabur India said the United States Food and Drug Administration (USFDA) has issued an import alert covering drugs manufactured at part of its Silvassa facility in Dadra and Nagar Haveli. The company linked the action to an inspection that flagged data integrity and maintenance deficiencies. For any manufacturer exporting regulated products to the US, an import alert is a serious compliance marker because it can stop shipments at the border. Dabur, however, has maintained that the move has no material impact on its financials or operations. The company also clarified that its domestic products are not covered by the order. The development is being closely tracked because it ties directly to the credibility of manufacturing controls and record-keeping, two areas regulators treat as fundamental to product quality.

What an FDA import alert typically does

Dabur’s update comes in the context of how the USFDA uses import alerts. A product placed on an FDA import alert can be detained without physical examination unless the importer demonstrates that it has addressed the violations cited in the alert. This process is commonly referred to as detention without physical examination (DWPE) in industry discussions, and it effectively shifts the burden to the company and its importers to show compliance. Practically, that can disrupt supply chains, even if the underlying issue is confined to a particular line or product category. It can also increase documentation requirements and scrutiny for shipments tied to the listed site.

Inspection findings cited in reports

Dabur said the alert followed an inspection where the regulator flagged data integrity and maintenance lapses. Separately, Reuters reported last month, citing the inspection report, that the regulator found critical manufacturing records were falsified. The report said the alleged falsification was used to conceal that equipment meant to make certain products had been used for multiple other products. Reuters also reported that a live bird and bird droppings were found in the raw material warehouse, about 30 feet from packaging materials. These are the kinds of observations that regulators typically treat as high-risk because they relate to traceability, contamination controls, and the reliability of batch documentation.

Scope: Dabur says it is limited to a small section

Dabur clarified that the import alert pertains only to a small section of the Silvassa manufacturing facility. According to the company, the section is involved in private-label products. Dabur added that the affected products generate insignificant revenue for the company. The company said the broader Silvassa plant continues to operate normally, indicating that the rest of the site and other business activities are not covered by the order. This distinction is important because import alerts are sometimes interpreted as a full-site shutdown, but Dabur’s statement frames it as limited in operational scope.

Timeline disclosed by the company

Dabur said the USFDA conducted an inspection at the plant and issued inspectional observations, to which it submitted responses. It added that the regulator reviewed the company’s responses along with the Establishment Inspection Report (EIR). Following that review, Dabur said, the USFDA issued Import Alert 66-40 on June 10, 2026. While the company did not disclose the inspection dates in its statement, it positioned the import alert as a post-review outcome rather than an immediate step taken during the inspection itself.

Dabur’s response: corrective actions and testing claims

Dabur said it continues to engage with the US regulator by providing corrective and preventive action plans, while also taking actions to fix the identified gaps. The company also said multiple internal and independent third-party tests have not identified any out-of-specification issues or other concerns with its products. This point appears aimed at separating compliance gaps in systems and documentation from confirmed product quality failures. Dabur also said it is implementing alternate sourcing strategies for its US customers, indicating steps to reduce disruption for buyers while it works through the regulatory process.

What Dabur said about financial and operational impact

On impact, Dabur stated that the FDA action does not have any financial or operational impact. It also said the order has no material impact on the company’s financials, operations, or other business activities. In the same context, Dabur reiterated that domestic products are not impacted by the import alert. These statements collectively suggest the company views the affected activity as small relative to its overall business mix, and as contained within a limited portion of its manufacturing footprint.

Dabur’s US portfolio and why compliance matters

Dabur describes itself as one of the world’s largest suppliers of Ayurvedic products with a legacy of over 140 years. In the US, it sells a range of over-the-counter and consumer health products, including cough and cold rubs, antifungal creams, pain relief gels, and oral care products. For products in these categories, regulators place heavy emphasis on consistent manufacturing controls, hygienic storage practices, and dependable record systems. When inspection observations relate to data integrity, it can create a broader confidence issue because the regulator needs to trust that the data presented reflects what happened on the shop floor.

Key facts at a glance

What investors and customers may track next

The next practical milestones are likely to revolve around Dabur’s engagement with the USFDA and how quickly it can demonstrate that identified gaps have been closed. Since products on an import alert can be detained unless compliance is demonstrated, the operational focus for the US-facing supply chain will typically be on documentation, remediation evidence, and any follow-up interactions with the regulator. Dabur’s statement that it is arranging alternate sourcing for US customers suggests it is already working to protect continuity for buyers. For markets, the key variable is not just the immediate revenue exposure described as insignificant, but the pace at which regulatory confidence is restored and the alert can be addressed through documented corrective actions.

Conclusion

Dabur India has confirmed that the USFDA issued Import Alert 66-40 for drugs manufactured at a small section of its Silvassa facility after an inspection flagged data integrity and maintenance deficiencies. The company says domestic products are unaffected and the financial impact is not material, while it works with the regulator through corrective and preventive action plans and alternate sourcing for US customers. The next updates, based on Dabur’s own framing, are likely to come through its continuing submissions and engagement with the USFDA tied to the issues cited in the alert.